Fresenius Kabi Receives FDA Drug Shortage Assistance Award

SAN JUAN – Fresenius Kabi has received a Drug Shortage Assistance Award from the U.S. Food and Drug Administration (FDA).

The FDA recognized the role Fresenius played in helping mitigate a shortage of IV saline bags. The shortage was caused last year by supply disruptions at manufacturers affected by Hurricane Maria.

The global health care company specializes in medicines and technologies for infusion, transfusion and clinical nutrition. It is a leading developer, manufacturer and provider of injected and infused medicines in the United States.

“Our collaboration with the FDA is focused on helping clinicians and hospitals assure patients in the U.S. have access to the medicines they need. This recognition is a great compliment to the many Fresenius Kabi employees in various roles across our company who are needed to respond to the shortages which, unfortunately, continue to be an issue in the U.S.,” said John Ducker, president and CEO of Fresenius Kabi USA.

Working with drug manufacturers, the FDA helped prevent 132 drug shortages in 2017 and 115 in 2016. There were 35 new drug shortages in 2017 and 23 new shortages in 2016. Although there was a slight increase in shortages in 2017 compared with 2016, this is still lower than previous years, according to the agency.

Related Posts

• 

  FDA is departing from long-standing procedures to deal with public health crises, and this may foreshadow problems for COVID-19 vaccines
  FDA is departing from long-standing procedures to deal with public health crises, and this may foreshadow problems for COVID-19 vaccines
• 

  FDA’s COVID-19 Update
  FDA’s COVID-19 Update
• 

  FDA coronavirus update
  FDA coronavirus update
• 

  FDA Warns Seller Marketing Dangerous Chlorine Dioxide Products that Claim to Treat or Prevent COVID-19
  FDA Warns Seller Marketing Dangerous Chlorine Dioxide Products that Claim to Treat or Prevent COVID-19

You must be logged in to post a comment Login